Cargando…

Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461

CX-5461 is a G-quadruplex (G4) ligand currently in trials with initial indications of clinical activity in cancers with defects in homologous recombination repair. To identify more genetic defects that could sensitize tumors to CX-5461, we tested synthetic lethality for 480 DNA repair and genome mai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masud, Tehmina, Soong, Charles, Xu, Hong, Biele, Justina, Bjornson, Saelin, McKinney, Steven, Aparicio, Samuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105411/ https://www.ncbi.nlm.nih.gov/pubmed/33963218 http://dx.doi.org/10.1038/s41598-021-88988-w

Ejemplares similares

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
por: Xu, Hong, et al.
Publicado: (2017)

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
por: El Hassouni, Btissame, et al.
Publicado: (2019)

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
por: Sanij, Elaine, et al.
Publicado: (2020)

A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer
por: Chung, Shin-Yi, et al.
Publicado: (2022)

CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I
por: Lehman, Stacey L., et al.
Publicado: (2022)

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer
por: Cornelison, Robert, et al.
Publicado: (2021)

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma
por: Kang, Chang-Won, et al.
Publicado: (2022)

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response
por: Snyers, Luc, et al.
Publicado: (2022)

Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461
por: Li, Guihong, et al.
Publicado: (2018)

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
por: Xuan, Jiachen, et al.
Publicado: (2020)

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
por: Hilton, John, et al.
Publicado: (2022)

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
por: Quin, Jaclyn, et al.
Publicado: (2016)

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
por: Pan, Min, et al.
Publicado: (2021)

A transcriptional program associated with cell cycle regulation predominates in the anti-inflammatory effects of CX-5461 in macrophage
por: Wang, Jie, et al.
Publicado: (2022)

The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability
por: Mars, Jean-Clément, et al.
Publicado: (2020)

CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma
por: Li, Leiming, et al.
Publicado: (2016)

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461
por: Son, Jinbae, et al.
Publicado: (2020)

Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling
por: Xu, Xia, et al.
Publicado: (2021)

Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells
por: Negi, Sandeep S., et al.
Publicado: (2015)

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
por: Yan, Shunfei, et al.
Publicado: (2020)

The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers
por: Ismael, Mohammed, et al.
Publicado: (2019)

Inhibition of Tumor‐induced Angiogenesis by a Synthetic Lipid A Analogue with Low Endotoxicity, DT‐5461
por: Sato, Katsuaki, et al.
Publicado: (1995)

DT‐5461, a New Synthetic Lipid A Analogue, Inhibits Lung and Liver Metastasis of Tumor in Mice
por: Sato, Katsuaki, et al.
Publicado: (1992)

rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis
por: Negi, Sandeep S., et al.
Publicado: (2015)

Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer
por: Simoneau, Antoine, et al.
Publicado: (2023)

G-Quadruplex DNA as a Molecular Target for Induced Synthetic Lethality in Cancer Cells
por: McLuckie, Keith I. E., et al.
Publicado: (2013)

Identifying collateral and synthetic lethal vulnerabilities within the DNA-damage response
por: Pinoli, Pietro, et al.
Publicado: (2021)

Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response
por: Kciuk, Mateusz, et al.
Publicado: (2022)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

PB2380: DEVELOPING GENOMIC TESTS THAT GUIDE LARGE B-CELL LYMPHOMA DIAGNOSIS AND TREATMENT: LYMPH2CX AND LYMPH3CX ASSAYS
por: Robetorye, Ryan S., et al.
Publicado: (2023)

Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?
por: Lazo, Pedro A.
Publicado: (2022)

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
por: Mandal, Jayaprakash, et al.
Publicado: (2022)

P1287: DISTINGUISHING BETWEEN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA USING THE LYMPH3CX GENE EXPRESSION PROFILING ASSAY
por: Robetorye, R. S., et al.
Publicado: (2022)

Protease Addiction and Synthetic Lethality in Cancer
por: Freije, José M. P., et al.
Publicado: (2011)

Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016)

Protocol for Comprehensive Synthetic Lethality Screens
por: Romero-Moya, Damia, et al.
Publicado: (2020)

The tumor therapy landscape of synthetic lethality
por: Zhang, Biyu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lmlqqhv1uuq4n3ap2ouifoghhi